Tozorakimab Dose 1 for Chronic Obstructive Pulmonary Disease

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Research Site, Liege, BelgiumChronic Obstructive Pulmonary DiseaseTozorakimab - CombinationProduct
Eligibility
40 - 130
All Sexes
What conditions do you have?
Select

Study Summary

This trial studies safety & effectiveness of a new COPD treatment. Subjects may be offered a chance to join an extension study.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease (COPD)

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: 104 weeks total (52 weeks in this study)

Week 104
Annualised rate of moderate to severe COPD exacerbations.
Annualised rate of severe COPD exacerbations.
Incidence of anti-drug antibodies.
Time to all-cause death.
Time to first moderate-to-severe COPD exacerbation.
Time to first severe COPD exacerbation in former smokers.
Time to first severe COPD exacerbation.
Trough serum concentrations of tozorakimab over the treatment period.

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

3 Treatment Groups

Tozorakimab Dose 1
1 of 3
Tozorakimab Dose 2
1 of 3
Placebo
1 of 3

Experimental Treatment

Non-Treatment Group

2544 Total Participants · 3 Treatment Groups

Primary Treatment: Tozorakimab Dose 1 · Has Placebo Group · Phase 3

Tozorakimab Dose 1
CombinationProduct
Experimental Group · 1 Intervention: Tozorakimab · Intervention Types: CombinationProduct
Tozorakimab Dose 2
CombinationProduct
Experimental Group · 1 Intervention: Tozorakimab · Intervention Types: CombinationProduct
Placebo
CombinationProduct
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: CombinationProduct

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 104 weeks total (52 weeks in this study)

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,021 Previous Clinical Trials
240,378,910 Total Patients Enrolled

Eligibility Criteria

Age 40 - 130 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You take medication that weakens your immune system, including steroids, and will continue to take it during the study.

Frequently Asked Questions

Is the age range for this trial limited, and if so what are its upper limits?

"Adhering to the parameters of entry, individuals aged 40 and over but less than 130 can enroll in this medical trial." - Anonymous Online Contributor

Unverified Answer

How hazardous is the first dosage of Tozorakimab for patients?

"Our evaluations place Tozorakimab Dose 1's safety at 3, due to the presence of multiple rounds of data confirming efficacy and supporting data for its security." - Anonymous Online Contributor

Unverified Answer

In what geographical areas can this clinical trial be accessed?

"This study is currently enrolling patients at 10 sites, including the cities of Newport Beach, Pensacola and Tampa. To reduce travel requirements for potential participants, it may be prudent to choose a medical site close by." - Anonymous Online Contributor

Unverified Answer

Are there any remaining openings in this clinical research endeavor?

"As detailed on clinicaltrials.gov, this clinical trial has stopped recruiting participants at present. Initially posted on February 20th 2023 and last updated on the 15th of that same month, there are 472 other research studies actively seeking patients to join their trials right now." - Anonymous Online Contributor

Unverified Answer

Are there any criteria restricting participation in this experiment?

"This medical study is enrolling 2544 individuals aged 40 to 130 with chronic obstructive pulmonary disease. To be considered, applicants must have completed the treatment period of predecessor studies within 12 weeks prior and provide a negative urine pregnancy test result. Additionally, female participants need to attest that they are using contraception as agreed in earlier trials before being accepted into this research program. Ultimately, all potential participants must sign an informed consent document to qualify for involvement." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.